Support program has roots in Basel
The online program Selfapy supports people suffering from mental health conditions during the coronavirus lockdown. BaselArea.swiss has provided startup help by way of its DayOne initiative.
The regional business promotion organization BaselArea.swiss is implementing numerous measures to support medical innovations by way of its DayOne initiative. In this context, the DayOne Experts event was held back in February, which placed the focus squarely on the issue of mental health. The participants included Professor Gunther Meinlschmidt, Research Director at the Department of Psychosomatic Medicine at the University Hospital Basel, in addition to the Berlin-based startup Selfapy. Following the event in Basel, Meinlschmidt and Selfapy have developed an online course for people suffering from mental health disorders during the COVID-19 lockdown period.
The free Selfapy program begins with an informative talk over the telephone or via email. During the online course, participants receive access to interactive exercises, videos and informative texts. A psychologist supports the participants and answers any questions they might have. In addition, the participants will be assessed personally and receive feedback on their progress.
“We followed the approach of developing a relatively broad service to offer those affected”, comments Meinlschmidt in an interview published on the website of the International Psychoanalytic University Berlin. “It consists of 12 modules into which we poured general knowledge relating to coping mechanisms and resources in the context of catastrophes and mental illnesses, all connected with specific strategies tailored to the current COVID-19 situation”, he adds. The service can be used by anyone aged 18 or over and is aimed at “people who are feeling the strain and want to do something to improve their mental health and feel less stressed during the ongoing pandemic situation.”
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.Read More